The purpose of the study is to evaluate how well these treatments work in different molecular subgroups of kidney cancer. Participants will receive one of the treatments based on their specific molecular group, which is determined by analyzing tumor samples. The study will monitor the response to treatment, including whether the cancer shrinks or disappears, and how long patients live without the cancer getting worse. The treatments are administered through an intravenous route, meaning they are given directly into a vein.

Throughout the study, participants will be regularly assessed by investigators to track their response to the treatment. This includes checking for any changes in the size of the cancer and monitoring overall health. The study aims to provide valuable information on the effectiveness of these treatments for metastatic kidney cancer, potentially leading to improved treatment options for patients in the future.

The purpose of the study is to determine if the Quadratus lumborum block can decrease the need for additional pain relief after surgery. Participants will receive either the active treatment or a placebo. The study will monitor the amount of pain medication needed at various times after the anesthesia is administered, as well as the time it takes before the first pain medication is required. Additionally, the study will assess pain levels both at rest and during movement.

The trial will follow participants through their recovery process to gather data on how effective the pain management technique is in reducing the need for further pain relief. This information will help improve pain management strategies for patients undergoing kidney removal surgery due to renal cancer.

The purpose of the study is to see if supervised group exercise, which includes aerobic and resistance training, can improve the effectiveness of cancer treatment. Additionally, the study will investigate whether combining this exercise with atorvastatin can further enhance the response to cancer therapy. Participants will be divided into groups, with some receiving supervised exercise sessions and others managing their own exercise routines. Some participants will also take atorvastatin, while others may receive a placebo.

The study will take place over a period of time, with participants being monitored for changes in their cancer’s progression and overall health. The goal is to determine if these interventions can help slow down the cancer or improve survival rates. This research could provide valuable insights into new ways to support cancer treatment through lifestyle changes and medication.

The purpose of this study is to evaluate the safety and effectiveness of Oncobax®-AK when used alongside these immunotherapy treatments. The study is divided into two phases. In the first phase, the focus is on understanding how safe and tolerable the combination of Oncobax®-AK and immunotherapy is for patients with metastatic NSCLC or RCC who have low levels of Akkermansia bacteria. The second phase aims to assess how well this combination works in treating these cancers.

Participants in the study will receive repeated doses of Oncobax®-AK along with their immunotherapy treatment. The study will monitor the patients’ response to the treatment and any side effects they may experience. The goal is to gather information that could help improve treatment options for patients with advanced NSCLC and RCC. This study is expected to continue until September 2025.

Participants in this study will continue to receive atezolizumab or a comparator agent, which is another treatment used for comparison, if they were benefiting from it in the previous study. The treatment is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein. The study will observe patients over a long period to monitor their health and any side effects they may experience. This includes tracking any serious adverse events, which are unexpected medical problems that occur during treatment, and their severity.

The study will also look at the time from when patients start the treatment to when they may pass away from any cause, specifically for those who were part of a previous study called IMpower133. This trial aims to ensure that patients who were benefiting from atezolizumab can continue their treatment safely and effectively, while also gathering important information about the long-term effects of the medication.

Participants in the study will receive one of the following treatments: spinal morphine, which is derived from the opium poppy and administered directly into the spinal fluid, or intravenous lidocaine, a common local anesthetic given through a vein. Additionally, some patients will receive a combination of bupivacaine, another local anesthetic, and adrenaline, which helps prolong the effects of the anesthetic. The purpose of the study is to determine if these treatments can enhance recovery after surgery, as measured by a patient-centered outcome scale called “Quality of Recovery 15.”

The study will involve a random assignment of treatments to participants, and it will be conducted without the participants knowing which treatment they are receiving. The trial will monitor recovery progress, including pain levels and overall well-being, at various points after surgery. The goal is to find the most effective pain management strategy to improve the recovery experience for patients undergoing this type of surgery.

The purpose of this study is to evaluate how effective this combination treatment is in preventing the cancer from getting worse over a period of one year. During the study, patients will receive atezolizumab through an intravenous (IV) infusion, which means the medication is given directly into a vein. They will also undergo SABR, a precise form of radiation therapy that targets the cancer cells while minimizing damage to surrounding healthy tissue. The study will monitor patients’ health and the progression of their cancer over time.

Participants in the study will be observed to see if the treatment helps keep their cancer from progressing and to assess any side effects they may experience. The study aims to provide valuable information on the potential benefits and risks of using atezolizumab in combination with SABR for treating metastatic tumors. This research could contribute to developing more effective treatment options for patients with these types of cancer.